Humacyte adds Scott Coward and Paul Kuznik to board of directors
The two life science executives join as Humacyte prepares its dialysis access launch of the ATEV, the company said.
SEC filing
Latest
4 stories
Monday, September 28
Thursday, August 13
Humacyte registers two Symvess trials: adolescent Phase 3 study and adult Phase 4 real-world study
Wednesday, August 12
Humacyte reports ATEV outperformed AV fistula in Phase 3 dialysis trial
The company plans to file an sBLA in the second half of 2026 and start a Phase 2a coronary study in the third quarter, per its second-quarter 2026 update.
SEC filing